title: Intravitreal bevacizumab (avastin) as an adjuvant for the treatment of posterior scleritis.
abstract: We report a case of posterior scleritis effectively managed with intravitreal bevacizumab. A 71-year-old woman was diagnosed with posterior scleritis. Although she was initially treated with systemic steroids, her clinical presentation deteriorated. She was then treated with a single intravitreal injection of bevacizumab and aqueous humor collection. The aqueous level of vascular endothelial growth factor prior to the intravitreal injection was 880.51 pg/mL, greater than that in the healthy control group (p < 0.001). One month later, the scleritis was completely resolved, and the patient remained stable during six months of follow-up. Intravitreal bevacizumab appears to be an effective adjuvant therapy for patients with posterior scleritis.
authors.affiliation: Department of Ophthalmology, Hallym University Chuncheon Sacred Heart Hospital,#153 Gyo-dong, Chuncheon, Korea. jiwoneye@hallym.or.kr
authors.forename: Ji Won
authors.initials: JW
authors.lastname: Lim
authors.forename: Joo Hyun
authors.initials: JH
authors.lastname: Park
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D001082:Aqueous Humor / Q000378:metabolism; D000068258:Bevacizumab; D003937:Diagnosis, Differential; D005260:Female; D005451:Fluorescein Angiography; D005500:Follow-Up Studies; D005654:Fundus Oculi; D006801:Humans; D016209:Interleukin-8 / Q000378:metabolism; D058449:Intravitreal Injections; D033401:Microscopy, Acoustic; D015423:Scleritis / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D016209:Interleukin-8; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab